$ALTO

Alto Neuroscience Inc. reports Q3 results Wednesday, with analysts expecting a loss of $0.82 per share. The company, which has no revenue, has seen EPS estimates decline 2.68% over 60 days. Despite losses, analysts rate it a Strong Buy with a $38.67 price target, implying 39% upside. Investors focus on cash runway and trial progress, particularly ALTO-207 for treatment-resistant depression, with key readouts expected in 2027.

Alto Ingredients (NASDAQ:ALTO) signed a 3-year deal for 20M bushels of low-carbon corn, expecting earnings benefits from 2027. The company shifted focus to domestic sales and completed projects to increase capacity. Q3 operating cash flow was $13M, with $24M in cash and $108M in borrowing availability. Alto aims to capitalize on California's E15 legislation for ethanol demand.

Alto Ingredients (ALTO) reported Q3 EPS of $0.16, beating estimates by $0.05, with revenue of $257.9M, exceeding expectations. The stock is down 20.27% over 3 months but up 201.72% over 12 months. InvestingPro rates its financial health as 'great performance'.

Alto Ingredients, Inc. (ALTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Ingredients, Inc. Reports Third Quarter 2026 Results Q3 2026 Net Income of $12.7 Million, or $0.16 per Share Q3 2026 Adjusted EBITDA of $21.0 Million Pekin, Ill., November 4, 2026 – Alto Ingredients, Inc. (NASDAQ: ALTO) , a leading producer and distributor of re

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

NATHAN GILBERT E purchased 10,000 shares of Alto Ingredients, Inc. (ALTO) at $3.93 on 2026-09-14.

Alto Ingredients (ALTO) reported higher high-quality alcohol volumes (+3.6M gallons YoY) in Q2 2026, but narrower premiums over ethanol reduced revenues by $2.9M. Hedging strategies offset some impact, limiting net premium decline to 2 cents/gallon. Profitability increased modestly despite softer premiums. Shares fell 5.6% in the past month, underperforming peers. Forward P/S ratio is 0.34, below industry average 3.33. Earnings estimates declined 27.8% and 66.3% for 2026 and 2027, respectively.

Alto Ingredients (ALTO) reported Q2 2026 results in an earnings call. Net sales rose to $245.7M, adjusted EBITDA was $23.7M, and net income attributable to common stockholders was $11.4M ($0.15/diluted share). Full-year Section 45Z guidance is $15M to $16M. Management discussed capacity expansion, CO2 storage, and a $50M at-the-market equity program.

NATHAN GILBERT E purchased 50,000 shares of Alto Ingredients, Inc. (ALTO) at $4.15 ($0.21M total) on 2026-08-11.

Alto Ingredients, Inc. (ALTO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 5, 2026, Alto Ingredients, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Designated Agent”), The Benchmark Company, LLC